(in millions, except per share data) | Quarter Ended June 30, 2024 | Full-Year Ended December 31, 2024 | |||||||||||||||||||||||||||||||||
Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | Acquired IPR&D and Milestones Expense | Adjusted Diluted EPS Range | ||||||||||||||||||||||||||||||||
Low | High | Low | High | ||||||||||||||||||||||||||||||||
Previously announced guidance excluding Q2 2024 acquired IPR&D and milestones expense | $ | — | $ | 3.05 | $ | 3.09 | $ | 164 | $ | 11.13 | $ | 11.33 | |||||||||||||||||||||||
Q2 2024 acquired IPR&D and milestones expense | 937 | (0.52) | (0.52) | 937 | (0.52) | (0.52) | |||||||||||||||||||||||||||||
Guidance including Q2 2024 acquired IPR&D and milestones expensea | $ | 937 | $ | 2.53 | $ | 2.57 | $ | 1,101 | $ | 10.61 | $ | 10.81 |